A medical implant comprising a plurality of layers, each layer comprising a polymer and a plurality of uni-directionally aligned continuous reinforcement fibers.

A medical implant comprising a plurality of layers, each layer comprising a polymer and a plurality of uni-directionally aligned continuous reinforcement fibers.

The invention relates to 10H-benzo[g]pteridine-2,4-dione derivatives, to the production thereof, and to the use thereof.

The invention relates to 10H-benzo[g]pteridine-2,4-dione derivatives, to the production thereof, and to the use thereof.

The present invention relates to implantable endoluminal prosthesis for preventing stroke. The endoluminal prosthesis (1) consists of a braided framework (20) defining a cylindrical lumen (21) devoid of impermeable membrane. Said braided framework (20) is self-expandable comprising a plurality of layers (22, 23, 24) of wires (25) made of biocompatible material. Each layer forms a mesh. The meshes form a lattice with a plurality of wires (2) of given layers (22, 23, 24). The lattice defines polygonal opening units (26) when observed normal to a wall of the implantable endoluminal prosthesis (1). The diameter (Ø.sub.25) of wire (25) being at least 30 μm and at most 150 μm, the mean diameter (Ø.sub.27) of the inscribed circle (27) of the polygonal opening units (26) being at least 75 μm and at most 200 μm in fully expanded state. The braided framework (20) consists of at least 128 and at most 512 wires (25). The ratio (T.sub.1/Ø.sub.25) of the thickness (T.sub.1) of a wall of said implantable endoluminal prosthesis (1) to the diameter (Ø.sub.25) of wire (25) is at least 3.0. In a fully expanded state, the surface coverage ratio (SCR) of said braided framework (20) is more than 50% and less than 90%.

The present invention relates to implantable endoluminal prosthesis for preventing stroke. The endoluminal prosthesis (1) consists of a braided framework (20) defining a cylindrical lumen (21) devoid of impermeable membrane. Said braided framework (20) is self-expandable comprising a plurality of layers (22, 23, 24) of wires (25) made of biocompatible material. Each layer forms a mesh. The meshes form a lattice with a plurality of wires (2) of given layers (22, 23, 24). The lattice defines polygonal opening units (26) when observed normal to a wall of the implantable endoluminal prosthesis (1). The diameter (Ø.sub.25) of wire (25) being at least 30 μm and at most 150 μm, the mean diameter (Ø.sub.27) of the inscribed circle (27) of the polygonal opening units (26) being at least 75 μm and at most 200 μm in fully expanded state. The braided framework (20) consists of at least 128 and at most 512 wires (25). The ratio (T.sub.1/Ø.sub.25) of the thickness (T.sub.1) of a wall of said implantable endoluminal prosthesis (1) to the diameter (Ø.sub.25) of wire (25) is at least 3.0. In a fully expanded state, the surface coverage ratio (SCR) of said braided framework (20) is more than 50% and less than 90%.

Various aspects of the present disclosure provide compositions including a water-insoluble therapeutic agent and a gallate-containing compound. Other aspects provide methods of using such compositions.

Various aspects of the present disclosure provide compositions including a water-insoluble therapeutic agent and a gallate-containing compound. Other aspects provide methods of using such compositions.

Metal objects are treated by anodizing (P, SE) the metal object in contact with an acidic solution, and then subjecting the anodized metal object to a reversed voltage (VR). The anodizing is performed in two stages, firstly to passivate (P) with the formation of a surface layer, and secondly to form pits in this surface layer (SE). The second stage (SE) of anodizing is performed at a lower voltage than the first stage (P). After the reversed voltage step (VR) the metal object is then contacted with a biocidal metal-containing solution. Biocidal metal is absorbed into the surface of the metal object, resulting in improved biocidal properties. The lower voltage of the second stage anodizing (SE) results in reduced processing time.

Balloon catheters, methods for preparing balloon catheters, and uses of balloon catheters are disclosed. The balloon catheter includes an elongate member, an expandable balloon, and a coating layer overlying an exterior surface of the expandable balloon. The coating layer includes a total drug load of a hydrophobic therapeutic agent and a combination of additives including a first additive and a second additive. The hydrophobic therapeutic agent is paclitaxel, rapamycin, or paclitaxel and rapamycin. The first additive is a surfactant. The second additive is a chemical compound having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester groups.